Cargando…

Refining the definition of HER2‐low class in invasive breast cancer

BACKGROUND: Emerging evidence indicates that breast cancer (BC) patients whose tumours express HER2 protein without HER2 gene amplification (HER2‐low), can benefit from antibody–drug conjugates (ADC). However, the current definition of HER2‐low BC remains incomplete with low rates of concordance. Th...

Descripción completa

Detalles Bibliográficos
Autores principales:	Atallah, Nehal M, Toss, Michael S, Green, Andrew R, Mongan, Nigel P, Ball, Graham, Rakha, Emad A
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9826019/ https://www.ncbi.nlm.nih.gov/pubmed/36030496 http://dx.doi.org/10.1111/his.14780

Ejemplares similares

Differential response of HER2-positive breast cancer to anti-HER2 therapy based on HER2 protein expression level
por: Atallah, N. M., et al.
Publicado: (2023)

Ki67 assessment in invasive luminal breast cancer: a comparative study between different scoring methods
por: Lashen, Ayat, et al.
Publicado: (2022)

The characteristics and clinical significance of atypical mitosis in breast cancer
por: Lashen, Ayat, et al.
Publicado: (2022)

Ubiquitin-conjugating enzyme 2C (UBE2C) is a poor prognostic biomarker in invasive breast cancer
por: Kariri, Yousif, et al.
Publicado: (2022)

Prognostic significance of KN motif and ankyrin repeat domains 1 (KANK1) in invasive breast cancer
por: Kariri, Yousif A., et al.
Publicado: (2019)

Potential quality pitfalls of digitalized whole slide image of breast pathology in routine practice
por: Atallah, Nehal M., et al.
Publicado: (2021)

The clinical significance of cyclin B1 (CCNB1) in invasive breast cancer with emphasis on its contribution to lymphovascular invasion development
por: Aljohani, Abrar I., et al.
Publicado: (2022)

Mechanistic and Clinical Evidence Supports a Key Role for Cell Division Cycle Associated 5 (CDCA5) as an Independent Predictor of Outcome in Invasive Breast Cancer
por: Kariri, Yousif A., et al.
Publicado: (2022)

Defining the area of mitoses counting in invasive breast cancer using whole slide image
por: Ibrahim, Asmaa, et al.
Publicado: (2021)

The ITIM-Containing Receptor: Leukocyte-Associated Immunoglobulin-Like Receptor-1 (LAIR-1) Modulates Immune Response and Confers Poor Prognosis in Invasive Breast Carcinoma
por: Joseph, Chitra, et al.
Publicado: (2020)

Evaluation of tumour infiltrating lymphocytes in luminal breast cancer using artificial intelligence
por: Makhlouf, Shorouk, et al.
Publicado: (2023)

The prognostic significance of BMI1 expression in invasive breast cancer is dependent on its molecular subtypes
por: Althobiti, Maryam, et al.
Publicado: (2020)

The clinical and biological significance of HER2 over-expression in breast ductal carcinoma in situ: a large study from a single institution
por: Miligy, Islam M., et al.
Publicado: (2019)

Retinoid X receptor gamma (RXRG) is an independent prognostic biomarker in ER-positive invasive breast cancer
por: Joseph, Chitra, et al.
Publicado: (2019)

Nucleolar protein 10 (NOP10) predicts poor prognosis in invasive breast cancer
por: Elsharawy, Khloud A., et al.
Publicado: (2020)

RAD50 deficiency is a predictor of platinum sensitivity in sporadic epithelial ovarian cancers
por: Alblihy, Adel, et al.
Publicado: (2020)

Prognostic value of proliferation assay in the luminal, HER2-positive, and triple-negative biologic classes of breast cancer
por: Aleskandarany, Mohammed A, et al.
Publicado: (2012)

The prognostic significance of wild-type isocitrate dehydrogenase 2 (IDH2) in breast cancer
por: Aljohani, Abrar I., et al.
Publicado: (2019)

Clinicopathological and Functional Evaluation Reveal NBS1 as a Predictor of Platinum Resistance in Epithelial Ovarian Cancers
por: Alblihy, Adel, et al.
Publicado: (2021)

Unravelling the clinicopathological and functional significance of replication protein A (RPA) heterotrimeric complex in breast cancers
por: Algethami, Mashael, et al.
Publicado: (2023)

Untangling the clinicopathological significance of MRE11-RAD50-NBS1 complex in sporadic breast cancers
por: Alblihy, Adel, et al.
Publicado: (2021)

The prognostic significance of interferon-stimulated gene 15 (ISG15) in invasive breast cancer
por: Kariri, Yousif A., et al.
Publicado: (2020)

Concordance of HER2-low scoring in breast carcinoma among expert pathologists in the United Kingdom and the republic of Ireland –on behalf of the UK national coordinating committee for breast pathology
por: Zaakouk, Mohamed, et al.
Publicado: (2023)

Predictors of pathological complete response to neoadjuvant treatment and changes to post-neoadjuvant HER2 status in HER2-positive invasive breast cancer
por: Katayama, Ayaka, et al.
Publicado: (2021)

Combined HER3-EGFR score in triple-negative breast cancer provides prognostic and predictive significance superior to individual biomarkers
por: Ogden, Angela, et al.
Publicado: (2020)

HER2/HER3 heterodimers and p21 expression are capable of predicting adjuvant trastuzumab response in HER2+ breast cancer
por: Green, Andrew R., et al.
Publicado: (2014)

Oestrogen-regulated protein SLC39A6: a biomarker of good prognosis in luminal breast cancer
por: Althobiti, Maryam, et al.
Publicado: (2021)

Automated Image Analysis of HER2 Fluorescence In Situ Hybridization to Refine Definitions of Genetic Heterogeneity in Breast Cancer Tissue
por: Radziuviene, Gedmante, et al.
Publicado: (2017)

The prognostic significance of Flap Endonuclease 1 (FEN1) in breast ductal carcinoma in situ
por: Al-Kawaz, Abdulbaqi, et al.
Publicado: (2021)

Investigating AP-2 and YY1 protein expression as a cause of high HER2 gene transcription in breast cancers with discordant HER2 gene amplification
por: Powe, Desmond G, et al.
Publicado: (2009)

Low expression of G protein-coupled oestrogen receptor 1 (GPER) is associated with adverse survival of breast cancer patients
por: Martin, Stewart G., et al.
Publicado: (2018)

XRCC1 deficient triple negative breast cancers are sensitive to ATR, ATM and Wee1 inhibitor either alone or in combination with olaparib
por: Ali, Reem, et al.
Publicado: (2020)

A key genomic subtype associated with lymphovascular invasion in invasive breast cancer
por: Kurozumi, Sasagu, et al.
Publicado: (2019)

Elevated MMP9 expression in breast cancer is a predictor of shorter patient survival
por: Joseph, Chitra, et al.
Publicado: (2020)

AI-enabled routine H&E image based prognostic marker for early-stage luminal breast cancer
por: Wahab, Noorul, et al.
Publicado: (2023)

The frequency and clinical significance of DNA polymerase beta (POLβ) expression in breast ductal carcinoma in situ (DCIS)
por: Al-Kawaz, Abdulbaqi, et al.
Publicado: (2021)

The Biological and Clinical Significance of Glutaminase in Luminal Breast Cancer
por: Masisi, Brendah K., et al.
Publicado: (2021)

The solute carrier SLC7A8 is a marker of favourable prognosis in ER-positive low proliferative invasive breast cancer
por: El Ansari, Rokaya, et al.
Publicado: (2020)

Prolyl-4-hydroxylase Α subunit 2 (P4HA2) expression is a predictor of poor outcome in breast ductal carcinoma in situ (DCIS)
por: Toss, Michael S., et al.
Publicado: (2018)

Updated UK Recommendations for HER2 assessment in breast cancer
por: Rakha, Emad A, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_i2hraosk1rk2a9fj9mg5g2m2ms